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per equivalents will be recouped in less than two months. Over 5 years there were 
325 fewer infections in the copper arm at a cost per QALY of £262.84. ConClusions: 
The investigation allowed the derivation of a spreadsheet-based model that uses 
the best current published information and shows the rapid ROI of a copper inter-
vention. It also calculates the impact on bed days and quality-adjusted life years 
(QALY). The model is simple, transparent to those with knowledge of spreadsheets, 
and allows adaptation to specific local settings.
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Cost-EffECtIvENEss of a 13-valENt CoNjugatE PNEumoCoCCal 
vaCCINatIoN Program IN CoPD PatIENts agED ≥ 50 YEars IN sPaIN: 
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objeCtives: Patients with chronic obstructive pulmonary disease (COPD) are at risk 
of pneumococcal infection. A 13-valent pneumococcal-conjugate vaccine (PCV13) 
has recently been approved for adult protection against S. pneumoniae. This study 
estimated the clinical and economic consequences of vaccinating COPD patients 
aged ≥ 50 years with PCV13 compared to current vaccination recommendations using 
a 23-valent pneumococcal-polysaccharide vaccine, from the Spanish Healthcare 
System perspective. Methods: A microsimulation model with a Markov process 
accounting for risks and costs for invasive pneumococcal disease (IPD) and all-cause 
nonbacteremic pneumonia (NBP) was developed. Prevalence, mortality rates, vaccina-
tion and serotype coverage, and vaccination and disease-related costs (€ 2013) were 
based on published data. Vaccines effectiveness was modified by a waning effect 
over time. Herd-immunity and revaccination were not considered. Outcomes and 
costs (both discounted at 3%/year) were simulated 100 times with, 1.6 million COPD 
patients per simulation. Outcomes were pneumococcal cases averted and incremen-
tal cost–effectiveness ratio (ICER) in terms of cost per life-year gained (LYG). Sensitivity 
analyses were performed modifying the time horizon, discount rate and vaccination 
coverage. Results: Over a 5-year period, the use of PCV13 vs current vaccination 
strategy in adult COPD subjects would prevent 529 IPD cases, 6,329 inpatient-NBP 
cases, and 697 outpatient-NBP cases. Additionally, 231 IPD and 148 inpatient-NBP 
related deaths would be averted. The ICER was € 24,557/LYG for PCV13 vs current 
vaccination strategy. In sensitivity analyses, ICER ranged from € 26,986/LYG (when 
changing discount rate from 3% to 5%) to € 7,661/LYG (when changing vaccination 
coverage from 80% to 66%). Using a lifetime horizon 1,271 IPD cases, 10,294 inpatient-
NBP cases, and 2,072 outpatient-NBP cases would be prevented, with an ICER of € 5,030/
LYG. ConClusions: At a willingness-to-pay of € 30,000/LYG, PCV13 vaccination in 
COPD patients aged ≥ 50 years in Spain is a cost-effective strategy compared to cur-
rent vaccination recommendations under both 5-year and lifetime time horizons.
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lINEzolID for thE trEatmENt of PatIENts wIth CoNfIrmED mrsa 
NosoComIal PNEumoNIa IN NaNjINg, ChINa: a Cost EffECtIvE 
altErNatIvE to vaNComYCIN
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objeCtives: Vancomycin has been the treatment of choice for several years while lin-
ezolid is a relatively new alternative in China. Although clinical superiority of linezolid 
was demonstrated in a recent head-to-head clinical study, economic evaluation com-
paring the two treatments provides additional useful decision making information. 
This study aimed to compare the cost-effectiveness of linezolid versus vancomycin 
in treating confirmed MRSA NP from a payer’s perspective in Nanjing. Methods: 
A cost-effectiveness model primarily driven by the head-to-head clinical data 
(Wunderink, CID: 2012), was adapted with local published data and expert opinion 
on resource use and unit costs. The model structure and assumptions were verified 
to reflect local clinical practice. Both linezolid and vancomycin arms were assumed 
to have same life expectancy in full health upon discharge. The base case analysis 
considered 10-day treatment duration for both treatments. Scenario analyses were 
conducted by varying treatment duration, per day total costs in ICU and general ward, 
drug acquisition costs, and including costs for managing key adverse events. All costs 
were reported in 2012 Chinese RMB. Results: A higher treatment success rate by 
2.7% was predicted for linezolid. Both treatment arms were estimated to have very 
similar average total costs in the region of RMB 78,800 with the key cost drivers being 
drug acquisition costs and ICU per day total cost. The ICER for linezolid was RMB 163 
for each additional successfully treated patient. Dominance of linezolid attributed to 
greater treatment success but lower total cost was observed in most of the scenario 
analyses. The highest ICER was RMB 31,663 in the scenario where the acquisition cost 
of vancomycin reduced by 20%. ConClusions: Given the estimated low ICERs with 
dominance in most of the scenario analyses, linezolid can be considered a cost effec-
tive option compared to vancomycin in managing confirmed MRSA NP in Nanjing.
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objeCtives: Ventilator-associated pneumonia (VAP) is the most common nosocomial 
infection in the intensive care unit (ICU). It’s associated with significant morbid-
ity, increasing the ICU and hospital length of stay (LOS), and raising overall costs. 
Literature suggests that costs could be reduced using the most efficient empiric 
recommendation on health care spending per QALY gained, PCV13 NIP in Czech 
Republic can be considered cost-effective.
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ECoNomIC EvaluatIoN of fIDaxomICIN for thE trEatmENt of 
ClostrIDIum DIffICIlE INfECtIoNs (CDI) also kNowN as C. DIffICIlE-
assoCIatED DIarrhoEa (CDaD) IN IrElaND
Van Engen A.1, Casamayor M.2, Loftus F.3, Crimin E.3, Lacey L.4
1Quintiles, Hoofddorp, The Netherlands, 2Quintiles, Barcelona, Spain, 3Astellas Pharma Co Ltd., 
Dublin, Ireland, 4Lacey Solutions Ltd., Skerries, Ireland
objeCtives: Fidaxomicin is the first in a new class of macrocylic antibiotics, indi-
cated in adults for the treatment of Clostridium difficile infections (CDI) also known 
as C. difficile-associated diarrhoea (CDAD). The study objective was to perform a 
cost-utility analysis of fidaxomicin for the treatment of CDI compared to oral met-
ronidazole (used to treat initial non-severe CDI and first non-severe recurrence) and 
oral vancomycin (used to treat severe CDI and any non-severe recurrence beyond 
the first one). Methods: A Markov model was used to determine the cost-utility 
of fidaxomicin in the treatment of all adult CDI patients (base case), patients with 
severe CDI, and patients with initial CDI recurrences, respectively. The cycle length 
was 10 days. The patient enters the model in the CDI health state and is treated either 
with fidaxomicin, oral metronidazole or vancomycin for 10 days. The time horizon 
was one-year. Deterministic and probabilistic sensitivity analyses were performed. 
Health state utilities were derived from the literature. The perspective was that of 
the Irish Health Service Executive (HSE). Results: In the base case, fidaxomicin was 
dominant compared to current standard of care, resulting in cost savings of € 2,904 
and an incremental QALY gain of 0.031. The main drivers of cost-effectiveness were 
the reduction in rate of recurrence in patients treated with fidaxomicin and the cost 
of hospitalisation. Fidaxomicin was also found to be dominant for all patient sub-
groups. The ICERs were highly sensitive to recurrence rates. The probability of the 
cost-effectiveness of fidaxomicin in all CDI patients at a willingness to pay thresh-
old of € 45,000 per QALY gained was estimated to be approx. 82%. ConClusions: 
Fidaxomicin was dominant compared to current standard of care with an approx. 82% 
probability of being cost-effective in all CDI patients at a willingness to pay threshold 
of € 45,000 per QALY gained.
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objeCtives: To demonstrate the impact of influenza vaccination in currently non-rec-
ommended populations in the UK. To understand critical elements of influenza infec-
tion (herd-effect and productivity losses) and management of disease. Management 
includes direct medical, non-medical and indirect resources. Methods: A multi-
cohort, static, one-year Markov-model was constructed. Universal influenza mass 
vaccination of healthy individuals ≥ 6 months to ≤ 64 years was applied, using either 
trivalent (TIV) or quadrivalent (QIV) influenza vaccines. Current vaccination cover-
age rates for high risk persons were utilized as a proxy. Vaccine efficacy data were 
derived from Cochrane Databases (TIV) and meta-analyses (QIV). The impact of herd-
effect was evaluated by two different estimates from published literature, providing a 
range of results. A societal perspective was adopted and 2010 was the cost reference 
year. Results: Using the average influenza-B circulation and vaccine matching data 
of 2000 to 2010, between 71,000-82,000 additional cases will be prevented with QIV 
versus TIV in one influenza season. QIV is anticipated to prevent more medical vis-
its, complications, and hospitalisations (15,000-17,000); (8,000-9,300) and (889-1,044), 
respectively. QIV programme costs are higher due to acquisition costs compared to 
TIV, however influenza treatment and management costs are lower due to fewer 
cases/complications for direct medical, non-medical and indirect categories (absen-
teeism/presenteeism), (savings: £4,800,000-£5,700,000); (savings: £215,000-£253,000); 
(savings: £22,400,000-£26,400,000), respectively. In addition, future productivity losses 
caused by premature mortality are also minimized with maximal effect with QIV 
rather than TIV (savings: £5,100,000-£6,700,000). ConClusions: Herd-effect is a well 
understood and appreciated benefit of vaccinating children and mass vaccination 
within a population. This model suggests that there are vast benefits in universal 
mass vaccination of healthy persons in the UK with QIV instead of TIV, due to greater 
health-related benefits and lower treatment-related costs. However, vaccine acquisi-
tion costs need to be considered.
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thE ECoNomIC assEssmENt of aN ENvIroNmENtal INtErvENtIoN: 
DIsCrEtE DEPloYmENt of CoPPEr for INfECtIoN CoNtrol IN ICus
Taylor M., Chaplin S.
York Health Economics Consortium, York, UK
objeCtives: Health Economics evaluations are typically applied to medications or 
surgery costs, but this unique study has investigated the economic benefits of dis-
crete deployment of antimicrobial copper alloy touch surfaces in ICUs. Copper/cop-
per alloy surfaces have been shown to act as an adjunct to standard infection control 
practices in diverse clinical settings, continuously reducing contamination by over 
90%. A study by Salgado in 2013 investigated the use of copper surfaces in ICUs and 
reported a 58% reduction in hospital acquired infections. This study investigates the 
cost-effectiveness of this intervention. Methods: Following an extensive literature 
review and use of expert opinion a number of factors have been considered in this 
evaluation. These are the component costs of the items used in the ICU, the cost of 
and extra day in bed due to an infection, baseline infection rates and risk reduction 
of copper items. The model is based on a single room configuration in an intensive 
care unit with 20 beds in the UK using 6 critical items - bed rails, overbed tray table, 
chair, call button, data device and IV pole. The model has been created to show the 
economic impact of an environmental intervention. Results: The model predicts 
the cost of replacing key, frequently-touched surfaces in a 20-bed UK ICU with cop-
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objeCtives: To evaluate economic impact of linezolid (LZD) versus vancomycin 
(VAN) for treatment of confirmed methicillin-resistant Staphylococcus aureus(MRSA) 
nosocomial pneumonia (NP) in German health care system. Methods: A 4 week 
decision model was developed capturing 1st and 2nd line therapy. Published lit-
erature (primarily Wunderink 2012, reported 54.8% clinical efficacy for LZD vs. 
44.9% for VAN in modified Intent-to-Treat population at End of Study for treat-
ment of MRSA NP) and expert opinion provided clinical and resource use data, 
such as efficacy, mortality, adverse events (AEs), treatment duration, and length 
of hospital/ICU stay. German cost data was obtained from published literature. 
Base-case analysis used 10-day treatment duration. In event of treatment failure/
severe AEs on 1st-line therapy, drug was switched after 7 days. Costs were reported 
in 2012 Euros. Results: LZD was associated with minimally lower costs (€ 16,119 
vs. € 16,144), and greater overall treatment success compared to VAN, resulting 
in LZD ‘dominating’ VAN. About 80% of treatment costs were related to hospital 
stay, primarily ICU (72%). Drug therapy, physician visits, laboratory tests and AEs/
treatment failure each account for ≤ 5% of total costs. Several scenarios were 
tested by varying treatment duration (7 or 14 days), and varying discontinuation/
switch of therapy (at 5 or 10 days). In cases of shorter treatment duration (7 day) or 
delayed switch of therapy (at 10 day), linezolid continues to ‘dominate’. However, 
with 14 day treatment duration or early switch (at 5 day) linezolid becomes more 
costly, but still has greater effectiveness resulting in a relatively low Incremental 
Cost Effectiveness Ratio (ICER) of € 8,207 and € 2,343 per successfully treated 
patient. ConClusions: LZD is a cost-effective alternative to VAN for treatment 
of MRSA-confirmed NP, owing primarily to its higher clinical response rate. Future 
analyses should use other country costs/resource use data to test result generaliz-
ability and assess empiric treatment phase.
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objeCtives: Despite available treatment options chronic hepatitis C virus (HCV) 
infection remains a significant disease burden in Denmark, in particular among 
genotype 1 difficult-to-treat patients The aim of this study was to evaluate the 
cost effectiveness of boceprevir (BOC), a protease inhibitor, in combination with 
pegylated interferon plus ribavirin (PEG+R), compared to PEG+R alone, among treat-
ment naïve and treatment experienced genotype 1 HCV patients. Methods: A 
Markov model simulating antiviral therapy and disease progression was devel-
oped to estimate the lifetime health care costs and clinical outcomes of alternative 
treatment strategies. The model simulated the treatment regimens of dual therapy 
(PEG+R) and triple therapy (PEG+R+BOC), respectively, as recommended in the sum-
mary of product (SPC) and the Danish treatment guidelines. Data on clinical effi-
cacy was taken from phase III clinical trials (SPRINT-2 and RESPOND-2). Costs were 
measured in 2012 Danish Kroner (DKK) and clinical outcomes in quality adjusted 
life years (QALYs). The incremental cost-effectiveness ratio (ICER) was estimated 
for treatment naïve and experienced patients. Deterministic and probabilistic sen-
sitivity analyses (PSA) on clinical inputs, costs, health state utility values, and SVR 
rates were performed to assess the overall decision uncertainty. Results: The ICER 
for PEG+R+BOC therapy versus standard of care with PEG+R was DKK 241.774 for 
treatment naïve HCV patients and DKK 98.371 for treatment experienced patients. 
PSA for treatment naïve patients showed a probability of cost-effectiveness of 
PEG+R+BOC therapy compared to PEG+R of more than 65 % at a willingness-to-pay 
threshold of DKK 300.000 (approx. £30.000). ConClusions: From a Danish health 
sector perspective, the model suggests PEG+R+BOC therapy is cost effective in HCV 
genotype 1 patients to prevent development of late manifestations in the liver, 
such as cirrhosis and hepatocellular carcinoma (HCC) irrespectively of treatment 
experience status.
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Cost-EffECtIvENEss ComParIsoN of gENotYPE 1 hEPatItIs C vIrus (hCv) 
trEatmENts usINg tElaPrEvIr (tvr) IN PatIENts wIth mIlD fIBrosIs 
vErsus PatIENts wIth BrIDgINg fIBrosIs aND CIrrhosIs
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objeCtives: To estimate, from a Spanish Healthcare System perspective, the cost-
effectiveness of the usage of telaprevir (TVR) with peginterferon and ribavirin (PR) 
in patients with mild fibrosis (METAVIR F2) vs. patients with bridging fibrosis or 
cirrhosis (METAVIR scores F3 and F4, respectively). Methods: A decision tree model 
was developed to assess cost-efficacy of TVR+PR according to the degree of fibrosis 
and previous response to treatment in patients with HCV Genotype 1. Treatment 
costs were estimated excluding futility rules but contemplating the potential to 
shorten treatment in treatment-naïve and relapsers that are either F2 or F3. The 
efficacy of triple therapy treatment by patient type is derived from the TVR phase 
III clinical trials. To estimate cost-effectiveness, the following values were calcu-
lated for each alternative: the cost per cured patient and the number of cured and 
not cured patients assuming a fixed budget. Results: TVR+PR in F2 patients has 
a lower cost per cured patient than F3+F4 both in naïve patients (20% less) and in 
experienced patients (in relapsers: 5% less; in partial responders: 47% less; and in 
null responders: 39% less). This difference is statistically significant for naïve and 
partial responding patients. For a 1 million EUR investment in each patient type, 
resources allocated to F2 patients offers maximum cured patients (94 in F2 vs. 71 
in F3+F4) and minimum non-cured patients (37 in F2 vs. 58 in F3+F4). This conclu-
sion stands when different sensitivity analyses are conducted. ConClusions: The 
usage of TVR+PR in patients with mild fibrosis could be a more cost-effective alter-
native than in patients with bridging fibrosis or cirrhosis regardless of the patient’s 
previous response to treatment. A long-term cost-effectiveness analysis is required 
in order to validate this data.
therapy. The aim of this study was to assess the cost-effectiveness (CE) of Linezolid 
against generic Vancomycin as an empiric therapy for VAP patients, from the health 
care payer’s perspective. Methods: A decision-tree model was used to compare 
costs and effectiveness of Linezolid (600 mg/12 hours) and Vancomycin (1g / 12 
hours) (comparator) for a cohort of patients with VAP. Effectiveness measures were: 
microbiological success rates, mortality rates, ICU and ward LOS and overall costs. 
Effectiveness and epidemiologic data were collected from published literature. Local 
costs (2012 US$) were obtained from Costa Rica’s Health System official databases. 
The model used a 12-week time horizon and only direct medical costs were consid-
ered (hospital LOS, medication costs, hematologic, gastrointestinal and skin adverse 
events and lab exams). Monte Carlo probabilistic sensitivity analysis (PSA) was 
constructed. Results: Results showed Linezolid as more effective and less expen-
sive option for VAP. Clinical success rate was higher with Linezolid (64.4%) against 
Vancomicyn, (56.1%). Mortality was lower with linezolid (10.13% vs 15.74%). Average 
ICU (and ward) LOS was 18 (9) days with Linezolid and 22 (10) days with Vancomycin. 
Overall medical costs per patient were $87782.52 with Linezolid and $92771.51 with 
Vancomycin. CE analyses showed Linezolid is the dominant strategy. ConClusions: 
This is the first CE study for VAP developed in Costa Rica. Linezolid resulted as the 
cost-saving option for treating VAP patients in the Costa Rican clinical environment.
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Cost-EffECtIvENEss of tElaPrEvIr Plus PEgINtErfEroN/rIBavIrIN 
(tvr+Pr) vErsus PEgINtErfEroN/rIBavIrIN (Pr) IN trEatmENt-NaïvE 
gENotYPE 1 ChroNIC hEPatItIs C PatIENts wIth f2 fIBrosIs IN BrazIl
Morais A.D., Pereira M.L.
Janssen Cilag Farmaceutica, São Paulo, Brazil
objeCtives: To compare the cost-effectiveness of telaprevir associated with 
peginterferon and ribavirin (TVR+PR) compared to peginterferon and ribavirin (PR) 
alone in the treatment of patients with METAVIR scale F2) fibrosis and with previ-
ously untreated chronic hepatitis C genotype 1. Methods: Markov model, Curtis 
et al 2012, was adapted to a Brazilian public payer perspective. The model estimated 
chronic hepatitis C disease progression based on transition probabilities for a cohort 
of patients with F2 fibrosis. Clinical outcomes and drug dosage were taken from 
the phase-3 trial (Marcellin et al), with the SVR-rate for TVR+PR as 79% and 49% for 
PR in patients with F2 fibrosis. Drug costs of TVR and PR were gathered from the 
ministry of health website, www.comprasnet.gov.br. Costs associated with each 
disease state were gathered from a study by Barros et al. A discount rate of 3.5 % and 
a lifetime horizon were assumed. Results: TVR+PR therapy resulted in higher costs 
(R$ BRL57,164 vs BRL27,971) and better outcomes (278 cirrhosis avoided per 1,000 
patients) compared to PR alone. Treatment with TVR+PR resulted in 19.94 life years 
gained compared to PR alone with 19.19. TVR+PR was estimated to give a quality 
adjusted life year (QALY) expectancy of 13.83, 1.16 higher than with PR (12.67 QALYs), 
resulted in an incremental cost-effectiveness ratio (ICER) of R$23,734 per QALY 
gained. Compared to PR alone, the treatment with TVR+PR avoided about 11 deaths 
and 17 liver transplants per 1,000 treated patients. Treatment with TVR+PR resulted 
in an incremental cost of R$1,595 per liver transplant avoided and R$2,613 per death 
avoided compared to PR alone. ConClusions: Treating F2 fibrosis patients with 
TVR+PR was cost-effective compared with PR alone with an ICER below to the WHO 
recommended threshold. The benefits of TVR+PR treatment were clear with the low 
incremental cost per death or liver transplant avoided.
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Cost-EffECtIvENEss of aNtI-raBIEs ProPhYlaxIs aftEr ExPosurE to 
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objeCtives: WHO recommends Post-Exposure Prophylaxis (PEP) in countries like 
France, where rabies cases observed are linked to bats or imported. This study aims 
to assess effectiveness and cost-effectiveness of anti-rabies PEP algorithms in this 
low rabies risk countries. Methods: A model-based analysis simulated PEP admin-
istration incorporating risk of rabies according to exposure categories (CII: minor 
scratches; CIII: transdermal bite(s)), PEP strategy, and risk of death on car crash in 
trips to anti-rabies centers. Strategies compared were: A) No PEP for CII and CIII; B) 
vaccine for CIII only; C) vaccine for CII and CIII; D) vaccine+immunoglobulins for 
CIII only; E)vaccine for CII and vaccine+immunoglobulins for C III. We simulated the 
trajectory of 2,807 patients exposed to unobservable dogs in Metropolitan France, in 
2011. Model parameters were estimated from French and international literature. 
The probability that the dog to which the patient was exposed is rabid was 4x10-9 
and the average risk of death on car crash in trips to anti-rabies centers was 7x10-
7. Total vaccine, immunoglobulins and consultation costs for Zagreb regimens (4 
vaccine injections) were € 160, € 700 and € 70, respectively. Results: Strategy E led 
to the lowest number of rabies cases (4.36x10-8), the highest costs (€ 2,493,000), but 
also to 1.74x10-3 lethal car crashes. Strategy A had the highest number of rabies 
cases (5.71x10-6), but no risk of lethal crash and no costs; therefore it was the most 
effective and the least costly strategy. In the sensitivity analysis when the probability 
that the dog is rabid was> 1.4x10-6, strategy D becomes more effective than strategy 
A; and when> 1.4x10-4, strategy B becomes cost-effective (i.e. cost-effectiveness ratio 
vs. A> 3x French GPD= € 30,000). ConClusions: In 2011, in France, anti-rabies PEP 
appears to be less effective and more expensive than No PEP. These model-based 
results could be used by decision makers to establish national guidelines.
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